$29,567.70 ownership Payment -- Roche/Genentech to Dr. Richard Brown

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Roche/Genentech made a $29.6K ownership payment to Richard Brown, a Neurology specialist in City, WI. The payment was associated with Humira. Roche/Genentech reported a significant ownership interest payment of $29,567.70 to Dr. Richard Brown, a Neurologist. This payment, categorized as 'Ownership or Investment Interest', was made on March 20, 2026. The payment is associated with Humira, a drug commonly used in neurology.

Patient Guidance: What This Payment Means for You

This record indicates a financial relationship where a physician may have an ownership stake in a company that manufactures a drug they prescribe. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Ownership interests can be common in healthcare, but the size and nature of this specific investment warrant attention within the neurology specialty.

Regulatory Context: Sunshine Act Requirements

Physicians must disclose ownership interests in entities that manufacture or supply drugs or devices they prescribe or order, as required by the Sunshine Act.

Related Topics

This payment is related to the following healthcare transparency topics:

• ownership-interest
• neurology
• roche-genentech
• humira
• physician-payment
• cms-open-payments

Understanding ownership Payments

Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.

Frequently Asked Questions About This Payment

What was this $29.6K payment for?

This was a ownership payment of $29.6K from Roche/Genentech to Richard Brown, categorized as "Ownership or Investment Interest". It was associated with Humira. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Richard Brown accept pharmaceutical money?

Yes, Richard Brown received this $29.6K payment from Roche/Genentech. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Richard Brown's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this ownership payment?

A ownership payment of $29.6K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Neurology?

To compare this payment against Neurology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Neurology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Richard Brown's relationship with Roche/Genentech?

The payment amount is substantial, indicating a potentially significant investment. This $29.6K ownership payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Neurology?

The payment type is 'ownership or investment interest', which differs from typical consulting or speaking fees.

What should patients do after learning about this payment?

This record indicates a financial relationship where a physician may have an ownership stake in a company that manufactures a drug they prescribe.

What else should I know about this ownership payment?

The specific drug associated, Humira, is a biologic often prescribed for autoimmune conditions managed by neurologists.

Related Reports

• View Dr. Richard Brown's full payment report
• Roche/Genentech full spending report
• Browse all Neurology payments
• Browse all payments in Wisconsin
• Search for other payments